Active Supportive Care and Symptom Management Grants

PI Name Organization - Company Titlesort ascending FOA
Prigerson, Holly Gwen Weill Medical Coll Of Cornell Univ Behavioral and Psychosocial Effects on Study Outcomes in End-Stage Cancer Treatment (BEST End-Stage Cancer Study) PAR-21-333: NCI Outstanding Investigator Award
Yeh, Chao Hsing University Of Texas Hlth Sci Ctr Houston Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Lin, Po-Ju University Of Rochester Assessing the role of the interoceptive brain system in the pathophysiology and treatment of chemotherapy-induced peripheral neuropathy PAR-20-292: NCI Clinical and Translational Exploratory/Developmental Studies
Albertson, Donna G New York University Artemin overexpression in oral cancer pain and carcinogenesis PA-18-484: NIH Research Project Grant
Sanft, Tara B Yale University A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence PAR-16-122: Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival
Zhou, Eric S Dana-Farber Cancer Inst A Preventive Care Approach to Mitigate the Impact of Pediatric ALL Treatment on Sleep PAR-20-052: NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022
Lee, Richard T Beckman Research Institute/City Of Hope A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy PAR-20-292: NCI Clinical and Translational Exploratory/Developmental Studies
Kober, Kord Michael University Of California, San Francisco An Investigation of the Molecular Mechanisms for and Prediction of the Severity of Cancer Chemotherapy-Related Fatigue Using a Multi-staged Integrated Omics Approach PA-21-071: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
Basch, Ethan M. Univ Of North Carolina Chapel Hill Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability
Gray, Robert J Dana-Farber Cancer Inst Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV) RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability
Sharafeldin, Noha University Of Alabama At Birmingham A multi-component non-pharmacological intervention to improve cognitive outcomes in hematologic cancer survivors PAR-20-052: NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022
Wang, Hsiao-Lan University Of Alabama At Birmingham A Motion Exergaming Approach to Promote Self-Managing Fatigue and Pain after Head and Neck Cancer Treatment PA-21-268: Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
Wen, Kuang-Yi Thomas Jefferson University A Mobile TXT-based Intervention to Improve Adherence to Adjuvant Hormone Therapy and Symptom Management for BCa Survivors PA-18-004: Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
Somers, Tamara J Duke University A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial PA-18-141: Mechanisms, Models, Measurement, and Management in Pain Research
Tighiouart, Mourad Cedars-Sinai Medical Center Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability

Pages